Myths and Facts about Placebo


 Placebo-effect, definition, bias, delta, nocebo.

How to Cite

Hans-Joachim Kremer. (2016). Myths and Facts about Placebo . Journal of Pharmacy and Nutrition Sciences, 6(2), 43–54.


Many patients, physicians, and sometimes even academics have questionable perceptions of placebo and the so-called placebo effect, Many believe that placebo have its own effects. Although psychological aspects, namely expectations of patients or the persuasive power of the physicians, might sometimes be substantial, such aspects may have little or even no relevance in other situation where placebo control is essential nevertheless. Even in settings where psychological effects should be envisaged, their extent is usually highly variable, indicating that other factors might still exceed the importance of psychological effects. Placebo is defined in US regulations as an inactive preparation designed to resemble the test drug as far as possible. This means that placebo itself cannot be effective. If it would, its correctness is challenged and it should be replaced if still possible. And as placebo is not effective, it can also not have secondary effects, vulgo side effects. Placebo is always used for two reasons: To control bias and to provide the reasonably largest delta, i.e. the difference between two treatments. Placebo should never be interpreted as being able to cause effects.


McDonald CJ, Mazzuca SA, McCabe GP Jr. How much of the placebo 'effect' is really statistical regression? Stat Med 1983: 2(4): 417-27.

Boutron I, Estellat C, Guittet L, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med 2006; 3(10): e425.

ICH E6: Guideline for Good Clinical Practice. May 1996, as adopted including including post step errata, status July 2002. Available from:

ICH E8: General Considerations for Clinical Trials. July 1997. Available from:

ICH E9: Statistical Principles for Clinical Trials. February 1998. Available from:

ICH E10: Choice of Control Group in Clinical Trials. July 2000. Available from:

European Commission: Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Published in the Official Journal L – 121, 01 May 2001, p. 34-44.

European Commission Regulation (EU) No 536/2014* of the European parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, Published in the Official Journal L 158/1, 27 May 2014, p. 1-76.

ICH E2A: Clinical safety data management: definitions and standards for expedited reporting (step 4: November 1994, step 5 (EU): June 1995).

European Commission: Communication form the Commission – Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use (‘CT-3’). 2011/C 172/01, Official Journal 11 June 2011

National Clinical Guideline Centre. Hypertension. Clinical management of primary hypertension in adults. London (UK): National Institute for Health and Clinical Excellence (NICE); 2011 Aug. 36 p. (Clinical guideline; no. 127). Available from:

Gomez HJ, Cirillo VJ, Sromovsky JA, et al. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 1989; 28(4): 415-20.

Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008; (4): CD003823.

Dupont AG, Van der Niepen P, Six RO. Placebo does not lower ambulatory blood pressure. Br J Clin Pharmacol 1987; 24(1): 106-9.

Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195-207.

Public Assessment Report of the Medicines Evaluation Board in the Netherlands. Crestor 5/10/20/40, 5/10/20/40 mg film-coated tablets, Astra Zeneca B.V., The Netherlands. 3 February 2011. Therein page 64. Available from:

Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152(11): 726-32.

Nowbar AN, Mielewczik M, Karavassilis M, et al. DAMASCENE writing group. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ 2014; 348: g2688.

Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344(21): 1594-602.

Hróbjartsson A, Gøtzsche PC. Placebo treatment versus no treatment. Cochrane Database Syst Rev 2003; (1): CD003974.

Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2004; (3): CD003974.

Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010; (1): CD003974.

Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5(12): e15591.

Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109(9): 1367-74.

Paul IM, Beiler JS, Vallati JR, Duda LM, King TS. Placebo effect in the treatment of acute cough in infants and toddlers: a randomized clinical trial. JAMA Pediatr 2014; 168(12): 1107-13.

Oduwole O, Meremikwu MM, Oyo-Ita A, Udoh EE. Honey for acute cough in children. Cochrane Database Syst Rev 2014; 12: CD007094.

Senn S. Placebo misconceptions. Am J Bioeth 2009; 9(9): 53-4.

Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2(8): e124.

Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 2012; 483(7391): 531-533.

Open Science Collaboration. PSYCHOLOGY. Estimating the reproducibility of psychological science. Science 2015; 349(6251): aac4716.

Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. Eur J Neurol 2013; 20(3): 527-33.

Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res 2014; 215(1): 82-6.

Dodd S, Schacht A, Kelin K, et al. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry 2015; 76(6): 702-11.

Eltiti S, Wallace D, Ridgewell A, et al. Does short-term exposure to mobile phone base station signals increase symptoms in individuals who report sensitivity to electromagnetic fields? A double-blind randomized provocation study. Environ Health Perspect 2007; 115(11): 1603-8.

Malek F, Rani KA, Rahim HA, Omar MH. Effect of Short-Term Mobile Phone Base Station Exposure on Cognitive Performance, Body Temperature. Heart Rate and Blood Pressure of Malaysians Sci Rep 2015; 5: 13206.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2016 Hans-Joachim Kremer